Biotechnology
/
Eastern Norway

Nerliens Meszansky AS

Africa
Asia
Denmark
Europe
North America
Oceania
South America
South Asia
Sweden
West Asia
  • Finance
    Operating income: 157.964
    Operating profit: 7.88
    Operating profit before tax: 8.338
    Total assets: 64.533
    Total equity: 20.151
    Currency: NOK (all numbers in thousands)
  • Management
    Board Chairman:
    Frederik Zimmer

    Board Members:
    Harald Høegh
    Marianne Sundsbø
    Stein Aukner
    Torsten Göran Brandt
    Øyvind Løken


    Subsidiary companies:
    Largest shareholders:
    N/A
    Biotechnology,